TY - JOUR
T1 - Apolipoprotein E genotypes and clinical outcome in Guillain-Barre syndrome
AU - Pritchard, J
AU - Hughes, R A C
AU - Rees, J H
AU - Willison, H J
AU - Nicoll, J A R
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Background: Polymorphism of the gene encoding the cholesterol transport protein apolipoprotein E ( APOE, gene; apoE, protein), known to be involved in axonal regeneration and remyelination, influences outcome after a variety of central nervous system disorders. Apolipoprotein E gene polymorphisms could affect recovery from Guillain-Barre syndrome. Objective: To correlate APOE genotypes with residual disability and degree of improvement in Guillain-Barre syndrome, assessed one year after presentation Methods: 91 patients with the syndrome were recruited from southeast England and their APOE genotypes were determined. Results: There were no clear differences in APOE genotype or allele frequencies when comparing the 91 patients with controls, nor when comparing 81 patients with good outcome and 10 with poor outcome. Conclusions: APOE genotype did not influence susceptibility to Guillain-Barre syndrome or recovery from it. This may be because our sample size of 91 was not sufficiently large to detect small differences in recovery associated with different APOE genotypes, or because cholesterol transportation is not a crucial rate limiting step in peripheral nerve regeneration.
AB - Background: Polymorphism of the gene encoding the cholesterol transport protein apolipoprotein E ( APOE, gene; apoE, protein), known to be involved in axonal regeneration and remyelination, influences outcome after a variety of central nervous system disorders. Apolipoprotein E gene polymorphisms could affect recovery from Guillain-Barre syndrome. Objective: To correlate APOE genotypes with residual disability and degree of improvement in Guillain-Barre syndrome, assessed one year after presentation Methods: 91 patients with the syndrome were recruited from southeast England and their APOE genotypes were determined. Results: There were no clear differences in APOE genotype or allele frequencies when comparing the 91 patients with controls, nor when comparing 81 patients with good outcome and 10 with poor outcome. Conclusions: APOE genotype did not influence susceptibility to Guillain-Barre syndrome or recovery from it. This may be because our sample size of 91 was not sufficiently large to detect small differences in recovery associated with different APOE genotypes, or because cholesterol transportation is not a crucial rate limiting step in peripheral nerve regeneration.
UR - http://www.scopus.com/inward/record.url?scp=0038141315&partnerID=8YFLogxK
U2 - 10.1136/jnnp.74.7.971
DO - 10.1136/jnnp.74.7.971
M3 - Article
SN - 1468-330X
VL - 74
SP - 971
EP - 973
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 7
ER -